Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

ClinicalTrials.gov ID: NCT07228390

Public ClinicalTrials.gov record NCT07228390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * have moderate or severe HS * have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose. Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone. The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.

Study identification

NCT ID
NCT07228390
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
128 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2025
Primary completion
Dec 7, 2026
Completion
Jan 4, 2027
Last update posted
Aug 31, 2026

2025 – 2027

United States locations

U.S. sites
35
U.S. states
16
U.S. cities
28
Facility City State ZIP Site status
Medical Dermatology Specialists Phoenix Arizona 85006
Mayo Clinic Hospital Phoenix Arizona 85054
Mayo Clinic Specialty Building Phoenix Arizona 85054
Mayo Clinic Scottsdale Arizona 85259
Burke Pharmaceutical Research Hot Springs Arkansas 71913
First OC Dermatology Research Inc Fountain Valley California 92708
Northridge Clinical Trials Northridge California 91325
Integrative Skin Science and Research Sacramento California 95815
Wolverine Clinical Trials Santa Ana California 92706
Skin Care Research Boca Raton Florida 33486
Olympian Clinical Research Largo Florida 33770
Ziaderm Research LLC North Miami Beach Florida 33162
D&H Tamarac Research Center Tamarac Florida 33321
NMC Research LLC Tampa Florida 33607
USF Health Tampa Florida 33612
Alliance Clinical Research of Tampa Tampa Florida 33615
Olympian Clinical Research Tampa Florida 33615
USF Florida Hearing Clinic Tampa Florida 33620
TruDerm & TruSpa Wellington Florida 33449
Advanced Medical Research, PC. Sandy Springs Georgia 30328
Endeavor Health Skokie Illinois 60077
The Indiana Clinical Trials Center, PC Plainfield Indiana 46168
Options Research Group West Lafayette Indiana 47906
Essential Medical Research - Overland Park Overland Park Kansas 66213
Skin and Hair Center Overland Park Kansas 66213
DS Research of Kentucky Louisville Kentucky 40241
Revival Research Institute, LLC Southfield Michigan 48034
Revival Research Institute, LLC Troy Michigan 48084
Skin Specialists, PC dba Schlessinger MD Omaha Nebraska 68144
Stracskin Portsmouth New Hampshire 03801
ClinOhio Research Services Columbus Ohio 43213
Columbia Dermatology & Aesthetics Columbia South Carolina 29212
Palmetto Clinical Trial Services - Greenville Greenville South Carolina 29615
Center for Clinical Studies, LTD. LLP Houston Texas 77004
Eurofins CRL Forest Virginia 24551

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07228390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07228390 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →